Abstract
OBJECTIVES: We assess the cost-effectiveness of switching from standard-dose quadrivalent influenza vaccination (SD-QIV) to high-dose vaccination (HD-QIV) for Dutch adults aged 60 years and older.
METHODS: A health-economic model was used to compare the scenario where HD-QIV was implemented compared to the current standard, SD-QIV. This model used a lifetime horizon and assessed the cost-effectiveness from a societal perspective. A recently published meta-analysis was used to incorporate the benefits of HD-QIV, including cardiorespiratory hospitalizations, in analyses considering RCT only or combining RCT and RWE estimates in a scenario analysis.
RESULTS: Implementing HD-QIV is cost effective at its list price, with an ICER of €5,400 per QALY gained. The main driver of these results is the prevention of cardiorespiratory hospitalizations. Other public health benefits are the prevention of GP consults and deaths. HD-QIV is highly likely to be cost-effective, reaching a 100% probability of being cost effective at the Dutch willingness-to-pay threshold of €20,000 per QALY.
CONCLUSIONS: Implementing HD-QIV for adults aged 60 and over within the existing influenza vaccination campaign is highly cost effective. HD-QIV may support alleviating potential capacity issues in Dutch hospitals in the winter respiratory season.
Original language | English |
---|---|
Pages (from-to) | 3429-3436 |
Number of pages | 8 |
Journal | Vaccine |
Volume | 42 |
Issue number | 15 |
Early online date | 17-Apr-2024 |
DOIs | |
Publication status | Published - 31-May-2024 |
Access to Document
Handle.net
Cost-effectiveness of high-dose influenza vaccination in the Netherlands
Final publisher's version, 1.18 MB
Licence: Taverne
Embargo ends: 17/10/2024
Request copy
Embargoed Document
Fingerprint
Dive into the research topics of 'Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations'. Together they form a unique fingerprint.
View full fingerprint
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
van der Pol, S., Zeevat, F., Postma, M. J. (2024). Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations. Vaccine, 42(15), 3429-3436. https://doi.org/10.1016/j.vaccine.2024.04.040
van der Pol, Simon ; Zeevat, Florian ; Postma, Maarten J et al. / Cost-effectiveness of high-dose influenza vaccination in the Netherlands : Incorporating the impact on both respiratory and cardiovascular hospitalizations. In: Vaccine. 2024 ; Vol. 42, No. 15. pp. 3429-3436.
@article{3a6767db66a34de29427e651d1efdee1,
title = "Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations",
abstract = "OBJECTIVES: We assess the cost-effectiveness of switching from standard-dose quadrivalent influenza vaccination (SD-QIV) to high-dose vaccination (HD-QIV) for Dutch adults aged 60 years and older.METHODS: A health-economic model was used to compare the scenario where HD-QIV was implemented compared to the current standard, SD-QIV. This model used a lifetime horizon and assessed the cost-effectiveness from a societal perspective. A recently published meta-analysis was used to incorporate the benefits of HD-QIV, including cardiorespiratory hospitalizations, in analyses considering RCT only or combining RCT and RWE estimates in a scenario analysis.RESULTS: Implementing HD-QIV is cost effective at its list price, with an ICER of €5,400 per QALY gained. The main driver of these results is the prevention of cardiorespiratory hospitalizations. Other public health benefits are the prevention of GP consults and deaths. HD-QIV is highly likely to be cost-effective, reaching a 100% probability of being cost effective at the Dutch willingness-to-pay threshold of €20,000 per QALY.CONCLUSIONS: Implementing HD-QIV for adults aged 60 and over within the existing influenza vaccination campaign is highly cost effective. HD-QIV may support alleviating potential capacity issues in Dutch hospitals in the winter respiratory season.",
author = "{van der Pol}, Simon and Florian Zeevat and Postma, {Maarten J} and Cornelis Boersma",
note = "Copyright {\textcopyright} 2024. Published by Elsevier India Pvt Ltd.",
year = "2024",
month = may,
day = "31",
doi = "10.1016/j.vaccine.2024.04.040",
language = "English",
volume = "42",
pages = "3429--3436",
journal = "Vaccine",
issn = "0264-410X",
publisher = "ELSEVIER SCI LTD",
number = "15",
}
van der Pol, S, Zeevat, F, Postma, MJ 2024, 'Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations', Vaccine, vol. 42, no. 15, pp. 3429-3436. https://doi.org/10.1016/j.vaccine.2024.04.040
Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations. / van der Pol, Simon; Zeevat, Florian; Postma, Maarten J et al.
In: Vaccine, Vol. 42, No. 15, 31.05.2024, p. 3429-3436.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Cost-effectiveness of high-dose influenza vaccination in the Netherlands
T2 - Incorporating the impact on both respiratory and cardiovascular hospitalizations
AU - van der Pol, Simon
AU - Zeevat, Florian
AU - Postma, Maarten J
AU - Boersma, Cornelis
N1 - Copyright © 2024. Published by Elsevier India Pvt Ltd.
PY - 2024/5/31
Y1 - 2024/5/31
N2 - OBJECTIVES: We assess the cost-effectiveness of switching from standard-dose quadrivalent influenza vaccination (SD-QIV) to high-dose vaccination (HD-QIV) for Dutch adults aged 60 years and older.METHODS: A health-economic model was used to compare the scenario where HD-QIV was implemented compared to the current standard, SD-QIV. This model used a lifetime horizon and assessed the cost-effectiveness from a societal perspective. A recently published meta-analysis was used to incorporate the benefits of HD-QIV, including cardiorespiratory hospitalizations, in analyses considering RCT only or combining RCT and RWE estimates in a scenario analysis.RESULTS: Implementing HD-QIV is cost effective at its list price, with an ICER of €5,400 per QALY gained. The main driver of these results is the prevention of cardiorespiratory hospitalizations. Other public health benefits are the prevention of GP consults and deaths. HD-QIV is highly likely to be cost-effective, reaching a 100% probability of being cost effective at the Dutch willingness-to-pay threshold of €20,000 per QALY.CONCLUSIONS: Implementing HD-QIV for adults aged 60 and over within the existing influenza vaccination campaign is highly cost effective. HD-QIV may support alleviating potential capacity issues in Dutch hospitals in the winter respiratory season.
AB - OBJECTIVES: We assess the cost-effectiveness of switching from standard-dose quadrivalent influenza vaccination (SD-QIV) to high-dose vaccination (HD-QIV) for Dutch adults aged 60 years and older.METHODS: A health-economic model was used to compare the scenario where HD-QIV was implemented compared to the current standard, SD-QIV. This model used a lifetime horizon and assessed the cost-effectiveness from a societal perspective. A recently published meta-analysis was used to incorporate the benefits of HD-QIV, including cardiorespiratory hospitalizations, in analyses considering RCT only or combining RCT and RWE estimates in a scenario analysis.RESULTS: Implementing HD-QIV is cost effective at its list price, with an ICER of €5,400 per QALY gained. The main driver of these results is the prevention of cardiorespiratory hospitalizations. Other public health benefits are the prevention of GP consults and deaths. HD-QIV is highly likely to be cost-effective, reaching a 100% probability of being cost effective at the Dutch willingness-to-pay threshold of €20,000 per QALY.CONCLUSIONS: Implementing HD-QIV for adults aged 60 and over within the existing influenza vaccination campaign is highly cost effective. HD-QIV may support alleviating potential capacity issues in Dutch hospitals in the winter respiratory season.
U2 - 10.1016/j.vaccine.2024.04.040
DO - 10.1016/j.vaccine.2024.04.040
M3 - Article
C2 - 38631948
SN - 0264-410X
VL - 42
SP - 3429
EP - 3436
JO - Vaccine
JF - Vaccine
IS - 15
ER -
van der Pol S, Zeevat F, Postma MJ, Boersma C. Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations. Vaccine. 2024 May 31;42(15):3429-3436. Epub 2024 Apr 17. doi: 10.1016/j.vaccine.2024.04.040